NCT07537881 2026-04-17
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Not yet recruiting
RemeGen Co., Ltd.
Henan Cancer Hospital
Mabwell (Shanghai) Bioscience Co., Ltd.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.